EUCTR2008-008276-14-BE进行中（未招募）1 期
A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic breast cancer.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed Informed Consent Form
- •Age = 18 years
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- •Histologically documented breast cancer
- •Locally advanced or metastatic breast cancer
- •For the purposes of this study, locally advanced breast cancer is defined as unresectable local or regional disease.
- •HER2-positive breast cancer documented as fluorescence in situ hybridization
- •(FISH)-positive, immunohistochemistry (IHC) 3 + or chromogenic in situ hybridization (CISH)-positive by local laboratory assessment
- •Confirmed availability (prior to Day 1) of tumor tissue blocks or 15-20 unstained tissue slides at screening for confirmatory central laboratory HER2 status testing and other exploratory assessments. Tissue specimens must be submitted within 60 days after the first dose of study drug.
- •Second or later line patients must have relapsed following or progressed on
- •HER2-directed therapy.
- •No prior T-DM1 or pertuzumab therapy
- •Measurable disease, defined as at least one lesion = 2 cm on computed
- •tomography (CT) scan or = 1 cm on spiral CT scan
- •Cardiac ejection fraction = 55% by either ECHO or MUGA scan.
- •Adequate hematologic and end organ function, defined by the following
- •laboratory results obtained within 14 days prior to study enrollment (defined as
- •the day the patient is assigned a subject number [not a screening number] via IVRS):
- •Absolute neutrophil count = 1500 cells/mm3
- •Platelet count = 100,000 cells/mm3
- •Hemoglobin = 9.0 g/dL
- •Total bilirubin = 1.5 × ULN
- •SGOT (AST) and SGPT (ALT) = 2.5 × ULN, with the following exception:
- •Patients with documented liver metastases: AST and/or ALT = 5 × ULN
- •Serum creatinine = 1.5 mg/dL, or creatinine clearance = 50 mL/min based
- •on Cockroft-Gault glomerular filtration rate (GFR) estimation:
- •(140 - age) × (weight in kg) × (0.85 if female)/72 × serum creatinine
- •For women of childbearing potential and men with partners of childbearing
- •potential, agreement to use a highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner, and to continue the use of contraception for the duration of study treatment and for at least 6 months after the last dose of study treatment. Male patients whose partners are pregnant should use condoms for the duration of the pregnancy.
- •Life expectancy = 90 days as assessed by the investigator
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Less than 21 days since the last anti-tumor therapy, including chemotherapy,
- •biologic, experimental, immune, hormonal or radiotherapy for the treatment
- •of breast cancer, with the following exceptions:
- •- Hormone-replacement therapy or oral contraceptives are allowed
- •- Palliative radiation therapy involving = 25% of marrow-bearing bone is allowed if administered = 14 days prior to first study treatment
- •History of intolerance or hypersensitivity to trastuzumab and/or adverse events
- •related to trastuzumab, murine proteins, or any of the excipients that resulted in
- •trastuzumab being permanently discontinued
- •Peripheral neuropathy of Grade = 2 per National Cancer Institute Common
- •Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0, at the time of, or within 3 weeks prior to, the first study therapy
- •History of exposure to the cumulative doses of anthracyclines listed below.
- •If another anthracycline or more than one anthracycline has been used, then the
- •cumulative dose must not exceed the equivalent of 500 mg/m2 of doxorubicin, using
- •the conversion factors provide in appendix F. The medical monitor should be
- •consulted if there are questions.
- •- Doxorubicin > 500 mg/m2 (or the equivalent dose of another anthracycline)
- •- Liposomal doxorubicin > 900 mg/m2
- •- Epirubicin > 720 mg/m2
- •History of clinically significant cardiac dysfunction, including:
- •- Current uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg), or unstable angina
- •- History of symptomatic CHF (Grade > 3 by NCI CTCAE or Class > II by New York Heart Association [NYHA] criteria, or serious cardiac arrhythmia requiring treatment, with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia
- •- History of myocardial infarction within 6 months prior to first study treatment
- •Current known active infection with HIV, hepatitis B virus, or hepatitis C virus
- •Pregnancy or lactation
- •Current severe, uncontrolled systemic disease (e.g., clinically significant
- •cardiovascular, pulmonary, or metabolic disease)
- •Patients with severe dyspnea at rest, due to complications of advanced malignancy, or requiring supplementary oxygen therapy are also excluded.
- •Major surgical procedure or significant traumatic injury within 28 days prior to first study treatment, or anticipation of the need for major surgery during the course of study treatment.
- •Symptomatic hypercalcemia requiring use of bisphosphonate therapy at the time of, or within 21 days of, the first study treatment
- •Patients who are receiving bisphosphonate therapy specifically for painful bony metastases or to prevent skeletal events and who do not have a history of clinically significant hypercalcemia are eligible.
- •Brain metastases that: Are untreated, or Are progressive, or Have required any type of therapy (including radiation, surgery, or steroids) to control symptoms from brain metastases within 60 days of the first study treatment.
- •History of other malignancy within the last 5 years, except for appropriately
- •treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome.
研究者
相似试验
进行中（未招募）
不适用
A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic breast cancerTreatment in patients with HER2-overexpressing locally advanced or metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-008276-14-DEF. Hoffmann-La Roche Ltd60
进行中（未招募）
1 期
A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic breast cancer who have progressed while receiving prior therapyTreatment in patients with HER2-overexpressing locally advanced or metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerEUCTR2008-008276-14-FRF. Hoffmann-la Roche Ltd40
进行中（未招募）
1 期
Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral GB2064 in participants with myelofibrosis.Primary (PMF) or secondary (SMF) myelofibrosis.MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003087-45-ITGalecto Biotech AB24
招募中
1 期
Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral GB2064 in participants with myelofibrosis.EUCTR2020-003087-45-DEGalecto Biotech AB24
进行中（未招募）
1 期
A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic breast cancer. - PIKHER2locally advanced, recurrent and metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002167-23-FRInstitut Paoli-Calmettes59